Reported research findings
- No human clinical trials have been run on N-Acetyl Semax specifically; the published clinical record belongs to the parent compound, Semax.
- Semax itself holds Russian regulatory approval and has been studied in randomized clinical work on ischemic stroke recovery and on cognitive endpoints in healthy volunteers.
- Whether the longer-acting version reproduces those results in people has not been tested.
